Veloxis Pharmaceuticals

Veloxis Pharmaceuticals is a U.S.-based, Asahi Kasei-owned company specializing in novel immunosuppressive therapies for solid organ transplant recipients. Its lead asset, VEL-101 (pegrizeprument), is a Phase 1 subcutaneous CD28 co-stimulation blocker with Orphan Drug Designation for liver transplant rejection, aiming to reduce toxicities of current standards. The company leverages its parent company's global network and resources to advance its pipeline while maintaining an agile, efficient operational model focused solely on the transplant therapeutic area.

Development of novel immunosuppressants, specifically a platform around pegylated monoclonal antibody fragments for selective CD28 blockade to inhibit T-cell activation while potentially preserving CTLA-4 regulatory function, formulated for subcutaneous self-administration.

The immunosuppression market is dominated by established drugs like tacrolimus and mycophenolate, with recent additions of biologics. Competition is intense, but most agents have serious side-effect profiles. Veloxis competes with other companies developing next-generation therapies (e.g., costimulation blockers, kinase inhibitors) aiming for better tolerability. Its unique CD28-specific mechanism and subcutaneous formulation could differentiate VEL-101 if clinically validated.